通过MAPK信号通路,MOTS-c可以预防乙氨基引起的肝损伤
Nan Li1,2, Yimin Xu3, Qixin Chen3
1Department of Anesthesiology, The Affiliated Suqian Hospital of Xuzhou Medical University, Suqian, China.
线粒体MOTS-c通过减少氧化应激和炎症来保护免受乙氨基诱导的肝损伤 (AILI). 通过抑制MAPK通路,MOTS-c显示出作为AILI的治疗方法的希望.
科学领域:
- 肝病学和分子医学 肝病学和分子医学
- 线粒体生物学 线粒体生物学
- 药物诱导的肝损伤研究研究
背景情况:
- 乙氨基诱导的肝损伤 (AILI) 是全球急性肝衰竭的主要原因,治疗选择有限.
- 线粒体衍生MOTS-c在其他肝脏疾病模型中表现出肝脏保护作用.
- 在AILI中MOTS-c的作用需要进一步调查.
研究的目的:
- 研究MOTS-c在乙氨基引起的肝损伤 (AILI) 的治疗潜力.
- 为了阐明MOTS-c在AILI中的保护作用的基础分子机制.
主要方法:
- 建立了一个使用乙氨基 (APAP) 注射的AILI小鼠模型.
- 使用生物化学测定,组织学和分子技术评估MOTS-c的治疗效果.
- 研究的机制包括氧化应激,炎症,亡和MAPK信号通路的激活.
主要成果:
- 在接受APAP治疗的小鼠中,MOTS-c的使用显著降低了肝损伤标志物 (AST,ALT) 和组织病理损伤.
- MOTS-c抑制了APAP诱导的炎症,巨细胞透,氧化应激和亡.
- MOTS-c抑制了MAPK通路的酸化 (ERK,JNK,p38),并阻止了这一通路,取消了MOTS-c的保护作用.
结论:
- 在小鼠中,MOTS-c显示出对APAP诱导的肝损伤具有显著的肝保护作用.
- 保护机制包括通过MAPK信号通路抑制氧化应激和炎症.
- MOTS-c是治疗乙氨基引起的肝损伤的有希望的治疗候选者.
更多相关视频
07:15Mechanism of Kemeng Fang's Inhibition of Podocyte Apoptosis in Rats with Membranous Nephropathy through the PI3K/AKT Signaling Pathway
Published on: August 23, 2024
09:44Generation of a Rat Model of Acute Liver Failure by Combining 70% Partial Hepatectomy and Acetaminophen
Published on: November 27, 2019
相关概念视频
MAPK Signaling Cascades
Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase
Phase II Reactions: Glutathione Conjugation and Mercapturic Acid Formation
Several distinctive characteristics distinguish glutathione conjugation from other phase II...
Phase II Reactions: Acetylation Reactions
The substrates for acetylation are typically drugs or their metabolites with an amino, sulfonamide, or hydrazine functional group. Acetylation can occur at several points in the drug molecule, including primary, secondary, and...
